Table 2.
Summary of the pooled results from meta-analysis
| Group | Studies | Cancer samples | Nonmalignant samples | OR with 95% CI | P | SE |
|---|---|---|---|---|---|---|
| Cancer vs. Benign | 3 | 175 | 170 | 77.93 (4.90–1238.45) | 0.002 | 1.411 |
| Cancer vs. Normal | 2 | 33 | 30 | 161.61 (17.65–1479.55) | < 0.001 | 1.13 |
| Clinicopathological characteristics | ||||||
| Gleason score (≥ 7 vs. ≤ 6) | 2 | 430 | 0.48 (0.27–0.85) | 0.012 | 0.293 | |
| T stage (T3–4 vs. T1–2) | 2 | 427 | 1.75 (0.78–3.91) | 0.175 | 0.411 | |
| Lymph node metastasis (Positive vs. Negative) | 2 | 430 | 27.89 (0.004–1.7e+ 05) | 0.455 | 4.481 | |
| Bone metastasis (Positive vs. Negative) | 2 | 59 | 145.80 (14.58–1458.02) | < 0.001 | 1.175 | |
OR odds ratio, 95% CI 95% confidence interval, SE standard error